一种基于肽适体技术的新型抗人血小板抗原抗体(HPA-1a)检测方法。
A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology.
机构信息
Université de Lyon, IBCP, UMR 5086 CNRS-Université Lyon, Lyon, France.
出版信息
Haematologica. 2012 May;97(5):696-704. doi: 10.3324/haematol.2011.051276. Epub 2011 Dec 1.
BACKGROUND
Neonatal alloimmune thrombocytopenia is mostly due to the presence of maternal antibodies against the fetal platelet antigen HPA-1a on the platelet integrin GPIIb-IIIa. Accurate detection of anti-HPA-1a antibodies in the mother is, therefore, critical. Current diagnostic assays rely on the availability of pools of human platelets that vary according to donors and blood centers. There is still no satisfactory standardization of these assays.
DESIGN AND METHODS
Peptide aptamer was used to detect and identify HPA-1a-specific antibodies in human serum that do not require human platelets. A peptide aptamer library was screened using an anti-HPA-1a human monoclonal antibody as a bait to isolate an aptamer that mimics the human platelet antigen HPA-1a.
RESULTS
This is the first report in platelet immunology of the use of a peptide aptamer for diagnostic purposes. This assay gives better results than the MAIPA currently in use, detecting around 90% of the expected alloantibodies.
CONCLUSIONS
This assay could help define a standard for the quantitation of anti-HPA antibodies. This report also demonstrates that peptide aptamers can potentially detect a variety of biomarkers in body fluids; this is of particular interest for diagnostic purposes.
背景
新生儿同种免疫性血小板减少症主要是由于母体血小板上存在针对血小板整合素 GPIIb-IIIa 上的胎儿血小板抗原 HPA-1a 的抗体。因此,准确检测母体中的抗 HPA-1a 抗体至关重要。目前的诊断检测方法依赖于人类血小板池的可用性,这些血小板池因供体和血液中心而异。这些检测方法仍然没有得到令人满意的标准化。
设计和方法
肽适体被用于检测和鉴定人血清中不需要人类血小板的 HPA-1a 特异性抗体。使用抗 HPA-1a 人单克隆抗体作为诱饵筛选肽适体文库,以分离模拟人类血小板抗原 HPA-1a 的适体。
结果
这是血小板免疫学中首次报道使用肽适体进行诊断目的。该检测方法比目前使用的 MAIPA 检测方法效果更好,可检测到约 90%的预期同种抗体。
结论
该检测方法有助于定义抗 HPA 抗体的定量标准。本报告还表明,肽适体有可能在体液中检测到各种生物标志物;这对于诊断目的特别有意义。